A Wall Street stock that aims to treat neurological conditions such as ADHD and autism has made a mystifying 64,000 per cent surge without selling a single product.
A Wall Street stock that aims to treat neurological conditions such as ADHD and autism has made a mystifying 64,000 per cent surge without selling a single product. Business / Companies Sydney Morning Herald – Latest News